Genspeed Biotech is developing the first COVID19 point-of-care assay that allows both infected and recovered patients to be tested in a single run in just minutes.
The development of the test is supported by the Austrian Research Promotion Agency under the COVID-19 Emergency Call. In its final stage, the combined test allows the simultaneous detection of antibodies as well as an acute viral infection in laboratory quality in just a few minutes. This makes the test unique in the world, as it can identify immune or acutely infected individuals for the first time on site, quickly and reliably. The range of applications is broad: whether for testing patients in doctors’ offices, staff and visitors in healthcare facilities or companies, or even travelers at airports.
Cooperation with medical research partners such as the Medical Faculty of the Johannes Kepler University, the Medical University of Graz, the Ludwig Boltzmann Institute and the BOKU in Vienna enable the highest quality in the implementation of the project. In any case, the first COVID-19 measurement results are very promising.
Kerstin Schanda
Corporate Communications
+43 664 819 3022
Kerstin.schanda@eoss.at